Literature DB >> 20209588

Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis.

Omar Barakat1, R Patrick Wood, Claire F Ozaki, Victor Ankoma-Sey, Joseph Galati, Mark Skolkin, Barry Toombs, Mary Round, Warren Moore, Luis Mieles.   

Abstract

In selected patients, locoregional therapy (LRT) has been successful in downstaging advanced hepatocellular carcinoma (HCC) so that the conventional criteria for liver transplantation (LT) can be met. However, the factors that predict successful treatment are largely unidentified. To determine these factors, we analyzed our experience with multimodal LRT in downstaging advanced HCC before LT in a retrospective cohort study. Thirty-two patients with advanced HCC exceeding conventional and expanded criteria for LT underwent therapy, but only those patients whose tumors were successfully downstaged were considered for LT. Eighteen patients (56%) had their tumors successfully downstaged; 14 patients (44%) did not. No intergroup differences existed with respect to patient characteristics or the types and number of treatments. However, mean alpha-fetoprotein levels were significantly higher in the non-downstaged group than in the downstaged group (P < 0.048), and significantly more patients in the non-downstaged group had infiltrative tumors (P = 0.0001). The median survival time was 42 and 7 months for the downstaged and non-downstaged groups, respectively (P = 0.0006). Fourteen patients (43.3%) underwent LT. After a median follow-up period of 35 months (range, 1.5-50 months) after LT, 2 patients (14.2%) developed tumor recurrence. The Kaplan-Meier survival rates after LT were 92% at 1 year and 75% at 2 years. The noninfiltrative expanding tumor type was the sole predictor of successful downstaging and improved outcome on univariate and multivariate analyses. Our study suggests that, in patients with advanced HCC, morphological characteristics of the tumor may predict a good response to downstaging and an improved outcome after LT.

Entities:  

Mesh:

Year:  2010        PMID: 20209588     DOI: 10.1002/lt.21994

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  30 in total

Review 1.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

2.  Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.

Authors:  Giuseppe Maria Ettorre; Giovanni Battista Levi Sandri; Andrea Laurenzi; Marco Colasanti; Roberto Luca Meniconi; Raffaella Lionetti; Roberto Santoro; Pasquale Lepiane; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Rita Golfieri; Gianpiero D'Offizi; Adriano M Pellicelli; Mario Antonini; Giovanni Vennarecci
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

3.  Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.

Authors:  Francis Y Yao; Neil Mehta; Jennifer Flemming; Jennifer Dodge; Bilal Hameed; Oren Fix; Ryutaro Hirose; Nicholas Fidelman; Robert K Kerlan; John P Roberts
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

Review 4.  Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.

Authors:  Arturo Soriano; Aranzazu Varona; Rajesh Gianchandani; Modesto Enrique Moneva; Javier Arranz; Antonio Gonzalez; Manuel Barrera
Journal:  World J Hepatol       Date:  2016-01-08

Review 5.  Downstaging for hepatocellular cancer: harm or benefit?

Authors:  Kathleen Bryce; Emmanuel A Tsochatzis
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-12

Review 6.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

7.  Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria.

Authors:  Jianyong Lei; Wentao Wang; Lunan Yan
Journal:  J Gastrointest Surg       Date:  2013-05-30       Impact factor: 3.452

Review 8.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

9.  Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.

Authors:  Neil Mehta; Nicholas Fidelman; Monika Sarkar; Francis Y Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

10.  Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis.

Authors:  Jian-Yong Lei; Wen-Tao Wang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.